Show results for
Refine by
Clinical Programs Articles & Analysis
14 articles found
In fact, cell therapy manufacturers need to take steps to ensure that reagents used for further manufacturing are removed before the cells are used in the clinic. Transition Program for GMP Cytokines - For each cytokine, Creative Bioarray provides a certificate of analysis, stability data, and bioactivity documentation for comparison to research-grade ...
In fact, cell therapy manufacturers need to take steps to ensure that reagents used for further manufacturing are removed before the cells are used in the clinic. Transition Program for GMP Cytokines - For each cytokine, Creative Bioarray provides a certificate of analysis, stability data, and bioactivity documentation for comparison to research-grade ...
Challenge Calculating the appropriate sample size for a first of its kind stage-II colon cancer trial As Chairman of the Department of Biostatistics, Professor Satoshi Teramukai leads a variety of investigator-initiated clinical trials at the Kyoto Prefectural University of Medicine. With over 35 years experience, hundreds of published papers and thousands of citations, Professor Satoshi ...
ByStatsol
He has worked in the leading CROs in the industry and has assisted pharmaceutical companies with the drug development process with clinical trials, programs, and portfolio designs. His experience extends from preclinical, phases I through IV, biosimilar, and bioequivalent using fixed, adaptive designs, stand-alone, and master protocols in multiple therapeutic ...
ByStatsol
Case in point: The pre-commercial drug developer counts dozens of programs in its pipeline including discovery and pre-clinical assets. Most young companies have less than 10 total programs. Recursion Pharmaceuticals will need billions of dollars to bring dozens of programs through clinical trials, regulatory ...
” And, although this has not yet been studied in clinical trials, other vessel preparation techniques, such as debulking with atherectomy, could also be employed pre-procedure in highly calcified vessels, he says. ...
Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. ...
The comprehensive cancer center designation means patients can access treatments exclusive to Karmanos, as well as clinical trials, cancer prevention programs, and multidisciplinary teams of cancer specialists — a comprehensive approach you cannot find in many large hospitals or health systems. ...
This presents an opportunity for stakeholders to align on short-, mid-, and long-term goals. Clinical stage pharma companies focus on clinical-trial related goals. These include completing ongoing clinical trials and initiating new ones, in the context of the company’s commercial plans as well as market pressures. ...
Whether your clinical operations team sits in a large sponsor company, or in one that’s still growing, it must be supported by efficient systems to maintain high productivity. Clinical trial protocols must be conducted with quality, within budget, and within timelines. To achieve this, Clinical Program Managers and ...
UH and CWRU coordinated one of the five Clinical Center Networks (CCNs) across the country selected to conduct the trial that had recruited more than 9,300 participants. ...
As a company, we are excited about accelerating our growth with resources behind our core clinical programs and product candidates.” Take 5 with BTL A privately held company that was founded in Prague 26 years ago, BTL has grown to 53 offices around the globe, 1,900 employees, 300+ engineers, five R&D centers, and two focused divisions. ...
Therapeutically, the company is studying the technology for over-the-counter analgesia and erythema. Dyve also has a late-stage clinical program, (DYV700) for the treatment of gout. “Melasma is a difficult condition to treat. A lot of it is patient-dependent on absolute diligence with sun protection,” says Joel Cohen, M.D., director of AboutSkin ...
SAN FRANCISCO, CA--(Marketwired - Sep 11, 2015) - Aelan Cell Technologies announced today the addition of Meenakshi Gaur, Ph.D. to their stem cell clinical program. Dr. Gaur will serve as the Director of Research and Development of the Stem Cell Program, leading a research team that will develop technology aimed at rejuvenation of human ...